Home
Ingunn Marie Stefansson's picture

Ingunn Marie Stefansson

Professor
  • E-mailIngunn.Stefansson@uib.no
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Scientific Reports. 1-11.
  • Show author(s) 2020. Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. Scientific Reports. 14 pages.
  • Show author(s) 2020. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • Show author(s) 2019. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 1-11.
  • Show author(s) 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Show author(s) 2017. Type of vascular invasion in association with progress of endometrial cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1084-1091.
  • Show author(s) 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Show author(s) 2017. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • Show author(s) 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Show author(s) 2017. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Scientific Reports. 1-12.
  • Show author(s) 2017. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. Cancer Immunology and Immunotherapy. 1463-1471.
  • Show author(s) 2016. Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival. Journal of Clinical Pathology. 313-319.
  • Show author(s) 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Show author(s) 2016. QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas. Modern Pathology. 1485-1491.
  • Show author(s) 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Show author(s) 2015. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
  • Show author(s) 2015. Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer. 459-466.
  • Show author(s) 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Show author(s) 2015. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
  • Show author(s) 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Show author(s) 2014. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
  • Show author(s) 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Show author(s) 2014. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: A Population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLOS ONE.
  • Show author(s) 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Show author(s) 2014. An 18-Gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer. PLOS ONE.
  • Show author(s) 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Show author(s) 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 pages.
  • Show author(s) 2013. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
  • Show author(s) 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Show author(s) 2013. Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. Diagnostic Pathology.
  • Show author(s) 2013. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
  • Show author(s) 2012. Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Research and Treatment. 501-510.
  • Show author(s) 2012. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 1-7.
  • Show author(s) 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • Show author(s) 2012. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 7 pages.
  • Show author(s) 2011. Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Research and Treatment. 1063-1071.
  • Show author(s) 2011. Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clinical Cancer Research. 3368-3377.
  • Show author(s) 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • Show author(s) 2011. Gene Expression Patterns Related to Vascular Invasion and Aggressive Features in Endometrial Cancer. American Journal of Pathology. 861-871.
  • Show author(s) 2011. Evolution in endometrial cancer evidence from an immunohistochemical study. International Journal of Gynecological Cancer. 316-322.
  • Show author(s) 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • Show author(s) 2009. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecologic Oncology. 491-495.
  • Show author(s) 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • Show author(s) 2009. Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology. 174-183.
  • Show author(s) 2009. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
  • Show author(s) 2008. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
  • Show author(s) 2008. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 307-316.
  • Show author(s) 2008. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 8713-8717.
  • Show author(s) 2006. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Research. 3303-3309.
  • Show author(s) 2006. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
  • Show author(s) 2006. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. International Journal of Cancer. 1227-1233.
  • Show author(s) 2006. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research. 1168-1174.
  • Show author(s) 2006. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
  • Show author(s) 2005. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer. 930-934.
  • Show author(s) 2005. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiology, Biomarkers and Prevention. 1108-1112.
  • Show author(s) 2004. The prognostic implication of the basal-like (cyclin E-high/p27(low)/p53(+)/glomeruloid-microvascular-proliferation(+)) phenotype of BRCA1-related breast cancer. Cancer Research. 830-835.
  • Show author(s) 2004. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology. 1615-1623.
  • Show author(s) 2004. Prognostic impact of histological grade and vascular invasion compared with tumor cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 472-479.
  • Show author(s) 2004. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. Journal of Clinical Oncology. 1242-1252.
  • Show author(s) 2004. Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
  • Show author(s) 2003. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1011-1018.
  • Show author(s) 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
  • Show author(s) 2002. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research. 138-43.
  • Show author(s) 2002. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2185-91.
Reader opinion piece
  • Show author(s) 2010. Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 641-646.
Doctoral dissertation
  • Show author(s) 2005. Biologic and prognostic markers of endometrial carcinoma.
Abstract
  • Show author(s) 2013. Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
  • Show author(s) 2013. Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
  • Show author(s) 2012. Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
  • Show author(s) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Show author(s) 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Show author(s) 2010. Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 248-248.
Poster
  • Show author(s) 2009. Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer.
  • Show author(s) 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • Show author(s) 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • Show author(s) 2006. Gene expression profiles identify an aggressive phenotype in endometrial carcinoma.

More information in national current research information system (CRIStin)